Vapreotide acetate for the treatment of esophageal variceal bleeding

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 2, 2008, Pages 185-192

  Calès, Paul ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cirrhosis; Gastrointestinal hemorrhage; Portal hypertension; Somatostatin; Variceal bleeding

Indexed keywords

ANTIBIOTIC AGENT; GLYCERYL TRINITRATE; OCTREOTIDE; PLACEBO; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; VAPREOTIDE; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ABDOMINAL DISCOMFORT; ACROCYANOSIS; ANGINA PECTORIS; ARTICLE; BILIARY TRACT DISEASE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; ISCHEMIA; LIVER CIRRHOSIS; LOOSE FECES; MEAN RESIDENCE TIME; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PORTAL HYPERTENSION; SCLEROTHERAPY; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING;

ANTINEOPLASTIC AGENTS; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; SOMATOSTATIN;

EID: 55649097728     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.2.185     Document Type: Article

References (57)

1. Dib N, Oberti F, Cales P. Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ 174(10), 1433-1443 (2006).
2. Pagliaro L. Portal hypertension in cirrhosis: natural history. In: Portal Hypertension: Pathophysiology and Treatment. Bosch J, Groszmann R (Eds). Blackwell Scientific Publications, Oxford, England, 190 (1994).
3. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N. Engl. J. Med. 345(9), 669-681 (2001).
4. Navarro VJ, Garcia-Tsao G. Variceal hemorrhage. Crit. Care Clin. 11(2), 391-414 (1995).
5. Burroughs AK, Mezzanotte G, Phillips A, McCormick PA, McIntyre N. Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 9(6), 801-807 (1989).
6. del Olmo JA, Pena A, Serra MA et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J. Hepatol. 32(1), 19-24 (2000).
7. Cales P, Masliah C, Bernard B et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N. Engl. J. Med. 344(1), 23-28 (2001).
8. Carbonell N, Pauwels A, Serfaty L et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 40(3), 652-659 (2004).
9. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin. Gastraenterol. 11(2), 243-256 (1997).
10. Nidegger D, Ragot S, Berthelemy P et al. Cirrhosis and bleeding: the need for very early management. J. Hepatol. 39(4), 509-514 (2003).
11. Boursier J, Asfar P, Joly-Guillou ML, Cales P. Infection and variceal bleeding in cirrhosis. Gastroenterol. Clin. Biol. 31(1), 27-38 (2007).
12. Avgerinos A. Approach to the management of bleeding esophageal varices: role of somatostatin. Digestion 59(Suppl. 1), 1-22 (1998).
13. Burroughs AK, Patch D. Therapeutic benefit of vaso-active drugs for acute variceal bleeding: a real pharmacological effect, or a side-effect of definitions in trials? Hepatology 24(3), 737-739 (1996).
14. McCormack G, McCormick PA. A practical guide to the management of oesophageal varices. Drugs 57(3), 327-335 (1999).
15. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J. Hepatol. 38(Suppl. 1), 554-S68 (2003).
16. Ferayorni L, Polio J, Groszmann R. Drug therapy for portal hypertension: a 5-year review. In:. Portal Hypertension II - Proceedings of the Second Baveno International Congress Workshop on Definitions, Methodology and Therapeutic Strategies. De Franchis R (Ed). Blackwell Science Ltd, London, UK, 68-97 (1996).
17. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 43(1), 167-176 (2005).
18. Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology 35(6), 1305-1312 (2002).
19. Groszmann R. Portal hypertension and esophageal variceal bleeding. In: Octreotide: The Next Decade. Lamberst S (Ed.). BioScientifica Ltd, Bristol, UK, 309-324 (1999).
20. Jamal M, Samarasena J, Hashemzadeh M. Nationwide trends in the incidence of bleeding and non-bleeding esophageal varices in hospitalized patients in the United States. Hepatology 44(Suppl. 1), 459-460 (2006).
21. Czernichow P, Hochain P, Nousbaum JB et al. Epidemiology and course of acute upper gastro-intestinal haemorrhage in four French geographical areas. Eur. J. Gastroenterol. Hepatol. 12(2), 175-181 (2000).
22. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 134(1), 301-306 (1994).
23. Cai RZ, Szoke B, Lu R et al. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl Acad. Sci. USA 83(6), 1896-1900 (1986).
24. Schally AV, Colaluca J, Paulson D et al. Effect of somatostatin analogs on gastric acid secretion in dogs and rats. Int. J. Pept. Protein Res. 36(3), 267-274 (1990).
25. Konturek SJ, Bilski J, Jaworek J, Tasler J, Schally AV. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proc. Soc. Exp. Biol. Med. 187(2), 241-249 (1988).
26. Cerini R, Lee SS, Hadengue A et al Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 94(3), 703-708 (1988).
27. Kravetz D, Bosch J, Arderiu MT et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am. J. Physiol. 254(3 Pt 1), G322-G328 (1988).
28. Lebrec D. Animal models of portal hypertension. In: Portal Hypertension. Clinical and Physiological Aspects. Okuda K, Benhamou J (Eds). Springer-Verlag. Tokyo, Japan, 101-112 (1991).
29. Veal N, Moal F, Oberti F, Vuillemin E, Cales P. Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis. Dig. Dis. Sci. 48(1), 154-161 (2003).
30. DebioPharm. Study DEB-93-VAP-05 (2007).
31. DebioPharm. Study DEB-98-VAP-08 (2007).
32. DebioPharm. Internal Study Report H3P VAP 09: a two-part pharmacokinetic study of vapreotide acetate in patients with renal or liver insufficiency and healthy volunteers (2002).
33. Villanueva C, Piqueras M, Aracil C et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J. Hepatol. 45(4), 560-567 (2006).
34. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46(3), 922-938 (2007).
35. Hochain P, Merle V, Tuil S et al. Transfusion for variceal bleeding in cirrhotic patients. Gut 38(1), 154 (1996).
36. Hebert PC, Wells G, Blajchman MA et al. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N. Engl. J. Med. 340(6), 409-417 (1999).
37. Hill SR, Carless PA, Henry DA et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst. Rev. 2, CD002042 (2002).
38. Calès P, Platt R. Survival benefit in patients with acute variceal bleeding and hemodynamic repercussions following early administration of vapreotide. Hepatalogy 46, 577A (2007).
39. Platt R, Calès P. Meta-analysis of early combination of vapreotide to endoscopic treatment in variceal bleeding. Gastroenterology 132(4 Suppl. 2), A799-A800 (2007).
40. DebioPharm. Study DEB-98-VAP-06: a double-blind, placebo-controlled, randomized study of vapreotide to prevent post-surgical complications in patients undergoing elective pancreatic resection (1998).
41. DebioPharm. Study DEB-01-VAP-07: the early association of vapreotide to endoscopic treatment for the control of acute variceal bleeding and prevention of early rebleeding in cirrhotic patients, a pilot study (2001).
42. DebioPharm. Study DEB-02-VAP-06: the early association of vapreotide to endoscopic treatment for the control of acute variceal bleeding and prevention of early rebleeding in cirrhotic patients (2002).
43. DebioPharm. Study DEB-97-VAP-02: the early association of vapreotide to endoscopic ligation for the control of acute cirrhotic variceal bleeding and prevention of early rebleeding (1997).
44. DebioPharm. Study DEB-92-VAP-02: study of RC160 administered as a continuous subcutaneous infusion in the treatment of malignant neuro-endocrine tumours with carcinoid syndrome (1992).
45. DebioPharm. Study DEB-93-VAP-09: efficacy of vapreotide acetate (Octastatin) administered in continuous s.c. infusion via micropump (Chronoclip) in acute Crohn's disease (1993).
46. DebioPharm. Study DEB-95-VAP-02: dose response study of GH inhibition in acromegaly by vapreotide when administered by continuous s.c. perfusion, a Phase IIa multicenter trial (1995).
47. Zaman A, Hapke RJ, Flora K, Rosen HR, Benner KG. Changing compliance to the American College of Gastroenterology guidelines for the management of variceal hemorrhage: a regional survey. Am. J. Gastroenterol. 99(4), 645-649 (2004).
48. Cheung J, Wong W, Zandieh I et al. Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey. Can. J. Gastroenterol. 20(8), 531-534 (2006).
49. Pilette C, Masson V, Oberti F et al. Coût du traitement hémostatique de l'hémorragie par rupture de varice oesophagiennes. Gastroenterol. Clin. Biol. 22, 244-245 (1995).
50. Thabut D, Hammer M, Cai Y, Carbonell N. Cost of treatment of oesophageal variceal bleeding in patients with cirrhosis in France: results of a French survey. Eur. J. Gastroenterol. Hepatol. 19(8), 679-686 (2007).
51. Besson I, Ingrand P, Person B et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N. Engl. J. Med. 333(9), 555-560 (1995).
52. Yan BM, Lee SS. Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can. JI. Gastroenterol. 20(3), 165-170 (2006).
53. Lebrec D, Vinel JP, Dupas JL. Complications of portal hypertension in adults: a French consensus. Eur. J. Gastroenterol. Hepatol. 17(4), 403-410 (2005).
54. Bosch J, Thabut D, Bendtsen F et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized., double-blind trial. Gastroenterology 127(4), 1123-1130 (2004).
55. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 40(4), 793-801 (2004).
56. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 350(9090), 1495-1499 (1997).
57. Levacher S, Letoumelin P, Pateron D et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 346(8979), 865-868 (1995).